Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Suraxavir Marboxil (GP681) Suspension vs Tablet in Healthy Chinese Males
NCT06678542Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of suraxavir marboxil in influenza (2 arms), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration and 1 more. Started Sep 2024; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06678542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678542.